Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00129441
Status:
COMPLETED
Last Update Posted:
2011-10-17
First Post:
2005-08-10
Brief Title:
Gamma-Amino Butyric Acid GABA-A Alpha23 Study
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha23 Receptor Agonist
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia
Detailed Description:
The goal of this study is to determine whether the short-term 4 week double-blind administration of Merck L-830982 provides evidence of improvement in cognitive functioning in stable male subjects with schizophrenia This initial small sample size study n9 on L-830982 and n6 on placebo is restricted to males in order to reduce the variance that might be attributable to the well-documented sex differences in the clinical features of schizophrenia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None